Evidence map›Paper›PMID 29369967›Full record

ArticlePain2018

Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain.

Kelsey M Nation, Milena De Felice, Pablo I Hernandez, David W Dodick, Volker Neugebauer, Edita Navratilova, Frank Porreca

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Pain, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06817018 (Ginger and the Microbiota-gut-brain Connection in Sciatic Pain Individuals), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06817018 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Ginger and the Microbiota-gut-brain Connection in Sciatic Pain Individuals

TypeinterventionalSponsorLeslie ShenRan2025 to 2028Enrolled80ConditionsNeuropathic Pain, Sciatic PainArmsPlacebo, Ginger
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Kelsey M NationGIDP in Neuroscience, University of Arizona, Tucson, AZ, USA.
Milena De FeliceDepartment of Pharmacology, University of Arizona, Tucson, AZ, USA. Dr. De Felice is now with the School of Clinical Dentistry, University of Sheffield, Sheffield, United Kingdom.
Pablo I HernandezDepartment of Pharmacology, University of Arizona, Tucson, AZ, USA. Dr. De Felice is now with the School of Clinical Dentistry, University of Sheffield, Sheffield, United Kingdom.
David W DodickMayo Clinic, Scottsdale, AZ, USA.
Volker NeugebauerDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Edita NavratilovaDepartment of Pharmacology, University of Arizona, Tucson, AZ, USA. Dr. De Felice is now with the School of Clinical Dentistry, University of Sheffield, Sheffield, United Kingdom.
Frank PorrecaGIDP in Neuroscience, University of Arizona, Tucson, AZ, USA.
University of Arizona · USMayo Clinic in Arizona · USTexas Tech University Health Sciences Center · USUniversity of Sheffield · GB

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
PAIN, NOCICEPTION, AND THE AMYGDALAR01NS038261 · NINDS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Volker Neugebauer, Igor Ponomarev · 1999 to 2026
$8.7M
Cortical opioid dysfunction in chronic painR01DA041809 · NIDA · UNIVERSITY OF ARIZONA · PI PORRECA, FRANK, WANG, ZAIJIE JIM · 2016 to 2020
$2.7M
Short-Term Training to Increase the Diversity Pipeline in Heart/Lung/Blood ResearchR25HL108837 · NHLBI · UNIVERSITY OF ARIZONA · PI WITTE, MARLYS HEARST · 2011 to 2021
$2.4M
Discovery of non-addictive KOR antagonists for migraine prophylaxisUH2NS093030 · NINDS · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTS, EDWARD · 2015 to 2015
$1.4M
NCI NIH HHS P30 CA023074NHLBI NIH HHS R25 HL108837NIDA NIH HHS R01 DA041809NINDS NIH HHS R01 NS038261NINDS NIH HHS UH2 NS093030
6 · The paper itself

Abstract

The response of diffuse noxious inhibitory controls (DNIC) is often decreased, or lost, in stress-related functional pain syndromes. Because the dynorphin/kappa opioid receptor (KOR) pathway is activated by stress, we determined its role in DNIC using a model of stress-induced functional pain. Male, Sprague-Dawley rats were primed for 7 days with systemic morphine resulting in opioid-induced hyperalgesia. Fourteen days after priming, when hyperalgesia was resolved, rats were exposed to environmental stress and DNIC was evaluated by measuring hind paw response threshold to noxious pressure (test stimulus) after capsaicin injection in the forepaw (conditioning stimulus). Morphine priming without stress did not alter DNIC. However, stress produced a loss of DNIC in morphine-primed rats in both hind paws that was abolished by systemic administration of the KOR antagonist, nor-binaltorphimine (nor-BNI). Microinjection of nor-BNI into the right, but not left, central nucleus of the amygdala (CeA) prevented the loss of DNIC in morphine-primed rats. Diffuse noxious inhibitory controls were not modulated by bilateral nor-BNI in the rostral ventromedial medulla. Stress increased dynorphin content in both the left and right CeA of primed rats, reaching significance only in the right CeA; no change was observed in the rostral ventromedial medulla or hypothalamus. Although morphine priming alone is not sufficient to influence DNIC, it establishes a state of latent sensitization that amplifies the consequences of stress. After priming, stress-induced dynorphin/KOR signaling from the right CeA inhibits DNIC in both hind paws, likely reflecting enhanced descending facilitation that masks descending inhibition. Kappa opioid receptor antagonists may provide a new therapeutic strategy for stress-related functional pain disorders.

Indexed as

Analgesics, OpioidAnimalsCapsaicinCentral Amygdaloid NucleusDynorphinsHypothalamusMaleMedulla OblongataMorphineNaltrexoneNarcotic AntagonistsPainRatsRats, Sprague-DawleyReceptors, Opioid, kappaStress, PhysiologicalAnalgesics, OpioidCapsaicinDynorphinsMorphineNaltrexoneNarcotic AntagonistsnorbinaltorphimineReceptors, Opioid, kappa

Identifiers

PMID29369967
PMCPMC5916844
OpenAlexW2801864057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.